NHS Greenlights Weight Loss Jabs for Over a Million Heart Patients
In a landmark decision, the National Health Service has approved the use of weight loss injections for more than one million individuals with heart disease across England. The move aims to significantly reduce the risk of heart attacks and strokes through what experts describe as a "life-changing" intervention.
Expanding Access to Semaglutide
The NHS's spending watchdog, the National Institute for Health and Care Excellence (Nice), has given the green light for semaglutide, sold under the brand name Wegovy, to be prescribed to overweight and obese patients with specific heart and circulatory conditions. This weekly injection, manufactured by Novo Nordisk, is a GLP-1 receptor agonist that mimics natural hormones to regulate blood sugar, appetite, and digestion.
While already available for treating obesity, the new guidance extends eligibility to approximately 1.2 million people in England who could benefit from this preventive approach. The drug will be used alongside existing medications like statins, combined with a reduced-calorie diet and increased physical activity.
Clinical Evidence and Expert Endorsement
Clinical trial data presented to Nice demonstrated compelling results. Among 17,604 participants, there was a 20 percent reduction in the risk of major heart events, including heart attacks, strokes, and cardiovascular deaths. Notably, this protective effect occurred even before significant weight loss was achieved.
Professor Naveed Sattar of the University of Glasgow hailed the decision as a "genuine win-win," stating: "We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease but also lead to meaningful weight loss. Given that many with cardiovascular disease struggle with excess weight, addressing weight directly is essential for optimal patient outcomes."
The Burden of Cardiovascular Disease
Cardiovascular disease remains one of the leading causes of death in the United Kingdom, with approximately 100,000 hospital admissions annually for heart attacks and a similar number of strokes each year. Excess body weight significantly elevates these risks by contributing to:
- Fatty deposits in arteries
- High blood pressure
- Elevated cholesterol levels
- Type 2 diabetes development
The British Heart Foundation emphasizes that clogged arteries from fatty buildup can directly trigger heart attacks, making weight management a critical component of cardiovascular care.
Implementation and Cost-Effectiveness
Nice's evaluation concluded that semaglutide is cost-effective for NHS use, with health service officials indicating it could be available within months. Helen Knight, director of medicines evaluation at Nice, noted: "The evidence from the clinical trial is compelling. People taking semaglutide alongside heart medicines were significantly less likely to have another heart attack or stroke."
Helen Williams, national clinical director for cardiovascular disease prevention at NHS England, added: "For over a million high-risk individuals, this treatment could be life-changing—offering a powerful new way to protect their hearts and improve health."
Broader Implications and Support
Health Minister Sharon Hodgson described the drug as a "game changer" for obesity management, extending its application to cardiovascular patients as a potential "life saver." Dr. Sonya Babu-Narayan of the British Heart Foundation reinforced this, stating: "These so-called 'weight loss drugs' have proven benefits beyond scale numbers—they are now vital medicines for preventing deadly heart events."
Sebnem Avsar Tuna, general manager for Novo Nordisk UK, welcomed the guidance as an "important step," highlighting it as the first GLP-1 receptor agonist proven to reduce cardiovascular risks in this high-risk population while being deemed cost-effective by Nice.
This expanded access marks a significant shift in preventive cardiology, integrating weight management directly into heart disease treatment strategies across England's healthcare system.
